Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Patent applications |
Patent application number | Title | Published |
20130089569 | RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS - The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA. | 04-11-2013 |
20130041267 | METHOD AND DEVICE FOR MULTI-SPECTRAL PHOTONIC IMAGING - An imaging device for medical imaging includes a light source device arranged to illuminate a sample under investigation with illumination light, a detector device arranged to collect a plurality of images including at least two sample light images backscattered by the sample in different spectral ranges, and at least one marker light image originating from at least one marker substance in the sample, and a processor device adapted to process the at least two sample light images and create at least one correction component, the processor device further adapted to correct the marker light image using the at least one correction component. | 02-14-2013 |
20130024959 | CONDITIONAL EXPRESSION OF TRANSGENES IN VIVO - The present invention relates to a method of producing a cell comprising a conditionally active transgene in its genome, the method comprising (a) introducing into the cell a targeting vector, wherein the targeting vector comprises (i) a 5′ recombinase recognition site specifically recognised by a first recombinase, wherein the first recombinase is endogenously present in the cell or wherein the first recombinase or a nucleic acid molecule encoding said first recombinase in expressible form is introduced into the cell; followed by (ii) a 5′ recombinase recognition site specifically recognised by a second recombinase, wherein the second recombinase is not endogenously present or is not active in the cell; followed by (iii) a selection cassette comprising a positively selectable marker gene; followed by (iv) a 3′ recombinase recognition site specifically recognised by a third recombinase, wherein the third recombinase is not endogenously present or is not active in the cell; followed by (v) the transgene; followed by (vi) a 3′ recombinase recognition site specifically recognised by a fourth recombinase, wherein the fourth recombinase is endogenously present in the cell or wherein the fourth recombinase or a nucleic acid molecule encoding said fourth recombinase in expressible form is introduced into the cell; wherein the genome of the cell comprises a 5′ recombinase recognition site and a 3′ recombinase recognition site that are identical to the recombinase recognition sites of (i) and (vi), and wherein said recombinase recognition sites comprised in the genome of the cell are located 3′ of an endogenous cellular promoter such that introduction of the targeting vector into the genome by site specific recombination results in the promoter being operatively linked to the selectable marker gene; and (b) culturing the cell in the presence of a selection medium specific for the selectable marker encoded by the selectable marker gene of (iii). The present invention further relates to a method of producing a conditional transgenic non-human mammalian animal as well as to a conditional transgenic non-human mammalian animal obtainable by said method. The present invention also relates to a transgenic TDP-43 mouse, comprising a transgenic cassette in intron 1 of the mouse Tardbp gene. | 01-24-2013 |
20120220851 | IMAGING DEVICE AND METHOD FOR OPTOACOUSTIC IMAGING OF SMALL ANIMALS - An imaging device configured for optoacoustic imaging of an object, including an illumination device including optical components arranged to illuminate the object, a detector device comprising an array of detector elements arranged in a tank and arranged to detect acoustic signals created in the object, and a container device including a tank arranged to accommodate the detector device, the object and a matching transmission medium, a holding device adapted to position and move the object relative to the illumination device and the detector device, wherein the optical components are arranged in the tank to illuminate the object from different directions. | 08-30-2012 |
20120123256 | THERMOACOUSTIC IMAGING WITH QUANTITATIVE EXTRACTION OF ABSORPTION MAP - A method of thermoacoustic imaging of an object includes providing thermoacoustic signals representing a mechanical wave response to a delivery of electromagnetic energy into the imaged object, reconstructing an energy deposition image representing a local energy absorption within the object based on the thermoacoustic signals, and decomposing the energy deposition image into a quantitative absorption image representing a distribution of a local absorption coefficient in the object and at least one further image component. | 05-17-2012 |
20120020940 | ANTIMICROBIAL PEPTIDES - The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well as a host cell comprising the nucleic acid molecule or the vector. The present invention also relates to a method for producing the peptide of the invention, a composition as well as to the peptide or peptidomimetic of the invention for use in treating infectious diseases. | 01-26-2012 |
20110306857 | QUANTITATIVE MULTI-SPECTRAL OPTO-ACOUSTIC TOMOGRAPHY (MSOT) OF TISSUE BIOMARKERS - A method of multi-spectral opto-acoustic tomography (MSOT) imaging of a target tissue including a target tissue biomarker includes illuminating the target tissue with an illumination device emitting at least one pulsed illumination pattern at several illumination wavelengths, detecting pressure signals from the target tissue biomarker with a detector device, wherein the pressure signals being produced in the target tissue are in response to the illumination, and reconstructing a quantitative tomographic image of a distribution of the target tissue biomarker in the target tissue, wherein the pressure signals are analyzed using a photon propagation model which depends on an illuminating light fluence in the target tissue and on the illumination wavelengths, at least one spectral processing scheme, and an inversion scheme providing the tomographic image. | 12-15-2011 |
20110294721 | ANTIMICROBIAL PEPTIDES - The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid residues; or a peptidomimetic thereof, wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well as a host cell comprising the nucleic acid molecule or the vector. The present invention also relates to a method for producing the peptide of the invention, a composition comprising the peptide or peptidomimetic of the invention as well as to the peptide or peptidomimetic of the invention for use in treating infectious diseases. | 12-01-2011 |
20110236409 | OVERLAPPING PEPTIDES FROM VARIABLE ANTIGENS, T CELL POPULATIONS AND USES THEREOF - The present invention relates to set overlapping immunogenic peptides of a variable antigen, and uses thereof, in particular for diagnostic and therapeutic purposes. The present invention relates also to a sub-population of CD8 T cells associated with the non-progressive status in HIV-infected subjects. | 09-29-2011 |
20110224477 | THERAPEUTIC DEVICE COMBINING RADIATION THERAPY AND THERMOTHERAPY - The disclosure relates to a therapeutic device for treatment of a patient, particularly for cancer treatment, which includes a radiation therapy apparatus for applying an ionizing radiation to the patient, and an integrated thermotherapeutic heating device for inducing a regional hyperthermia in the patient. | 09-15-2011 |
20110059443 | FLUORESCENT GFP VARIANT DISPLAYING HIGHLY INCREASED FLUORESCENCE INTENSITY WITHOUT A SPECTRAL SHIFT - The present invention relates to a nucleic acid molecule encoding a polypeptide having a fluorescence emission activity with a maximum emission at 505 to 515 nm, wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO: 1; (c) a nucleic acid molecule hybridizing under stringent conditions to the complementary strand of (i.) a nucleic acid molecule of (a), wherein said nucleic acid molecule of (c) encodes a polypeptide having at the position corresponding to position 146 of SEQ NO:2 a phenylalanine and at the position corresponding to position 203 of SEQ NO:2 a threonine; or (ii) a nucleic acid molecule of (b), wherein said nucleic acid molecule of (c) has at the positions corresponding to positions 438 to 440 of SEQ ID NO: 1 a nucleotide triplet selected from the group consisting of TTT and TTC; and at the positions corresponding to positions 609 to 611 of SEQ ID NO: 1 a nucleotide triplet selected from the group consisting of ACT, ACC, ACA, ACG; wherein the polypeptide encoded by the nucleic acid molecule of (c) has a fluorescence enhanced by at least the factor of 2.5 as compared to the polypeptide having the amino acid sequence of SEQ ID NO: 10; or (d) a nucleic acid molecule degenerate with respect to the nucleic acid molecule of (b). The present invention furthermore relates to a polypeptide encoded by the nucleic acid molecule of the invention, a vector and a host cell comprising the nucleic acid molecule of the invention, a method of producing said polypeptide, a fusion protein comprising the polypeptide of the invention and methods of detecting the presence and/or localization of a protein of interest and methods of detecting the activity of a promoter. | 03-10-2011 |
20100284976 | COMPOSITIONS FOR THE PREPARATION OF MATURE DENDRITIC CELLS - The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising said factors as well as to mature dendritic cells produced by the method of the invention. | 11-11-2010 |